首页> 外文期刊>American Journal of Kidney Diseases: The official journal of the National Kidney Foundation >Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor
【24h】

Diffuse proliferative glomerulonephritis associated with cetuximab, an epidermal growth factor receptor inhibitor

机译:与表皮生长因子受体抑制剂西妥昔单抗相关的弥漫性增殖性肾小球肾炎

获取原文
获取原文并翻译 | 示例
           

摘要

Cetuximab is an epidermal growth factor receptor inhibitor used for advanced squamous cell carcinoma of the head and neck. We report an unusual case of diffuse proliferative and crescentic glomerulonephritis in a 67-year-old man in close temporal association with cetuximab treatment for recurrent oral squamous cell carcinoma. The patient presented with acute renal failure and nephrotic-range proteinuria. Kidney biopsy showed diffuse proliferative and focally crescentic glomerulonephritis associated with immunoglobulin A (IgA)-dominant immune-complex deposition within glomerular capillary walls and mesangium. The patient showed dramatic improvement in kidney function after discontinuation of cetuximab therapy and a short course of cyclophosphamide and steroid. The clinical outcome of this case suggests that cetuximab therapy may trigger or exacerbate IgA-mediated glomerular injury and warrants close monitoring of kidney function in patients treated with this epidermal growth factor receptor inhibitor.
机译:西妥昔单抗是一种表皮生长因子受体抑制剂,用于晚期头颈部鳞状细胞癌。我们报告了一个不寻常的病例,该病例为一名67岁男性与西妥昔单抗治疗复发性口腔鳞状细胞癌密切相关的弥漫性增生和新月型肾小球肾炎。该患者表现为急性肾衰竭和肾病范围蛋白尿。肾脏活检显示弥漫性增生性和局灶性新月形肾小球肾炎,与免疫球蛋白A(IgA)为主的免疫复合物沉积在肾小球毛细血管壁和肾小球系膜中。停止西妥昔单抗治疗以及短期服用环磷酰胺和类固醇后,患者的肾脏功能显着改善。该病例的临床结果表明,西妥昔单抗治疗可能会触发或加剧IgA介导的肾小球损伤,并需要密切监测用这种表皮生长因子受体抑制剂治疗的患者的肾功能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号